Cover Image

Relevance of donor-specific antibody monitoring after kidney transplantation: findings from the Collaborative Transplant Study and the Heidelberg Transplant Center

Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitorin...

Full description

Saved in:
Bibliographic Details
Main Authors: Süsal, Caner (Author) , Aykut, Güçlü (Author) , Morath, Christian (Author) , Fichtner, Alexander (Author) , Unterrainer, Christian (Author) , Scherer, Sabine (Author) , Tran, Thuong Hien (Author) , Mehrabi, Arianeb (Author) , Zeier, Martin (Author) , Tönshoff, Burkhard (Author)
Format: Article (Journal)
Language:English
Published: 12 August 2019
In: HLA
Year: 2019, Volume: 94, Issue: S2, Pages: 11-15
ISSN:2059-2310
DOI:10.1111/tan.13665
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/tan.13665
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/tan.13665
Get full text
Author Notes:Caner Süsal, Güclü Aykut, Christian Morath, Alexander Fichtner, Christian Unterrainer, Sabine Scherer, Thuong H. Tran, Arianeb Mehrabi, Martin Zeier, Burkhard Tönshoff
Description
Summary:Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitoring in patients undergoing renal transplantation. The obtained findings underline the importance of DSA monitoring in the post-operative course in immunologically high-risk patients and patients with deterioration of graft function. Especially in patients with a pre-activated immune system, a gap in the immunosuppressive therapy appear to lead to persistence, reappearance or de novo occurrence of strong, complement-activating DSA, resulting in severe antibody-mediated rejection (AMR) and, without timely intervention, in AMR-related graft loss.
Item Description:Gesehen am 09.04.2020
Physical Description:Online Resource
ISSN:2059-2310
DOI:10.1111/tan.13665

Similar Items